AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24884501 — intervention group
Group type: COMPARATOR
Intervention: Nordic FLOX
Number of subjects: 504
Study 24884501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic FLOX and Nordic FLOX + cetuximab
Number of subjects: 504
Study 22409993 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified laparoscopic sleeve gastrectomy (MLSG)
Number of subjects: 150
Study 19693508 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercise program with EMG‐biofeedback
Number of subjects: 40
Study 19693508 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercise program without biofeedback
Number of subjects: 40
Study 18329189 — intervention group
Group type: COMPARATOR
Intervention: Good Behavior Game (GBG)
Number of subjects: 19
Study 18329189 — intervention group
Group type: COMPARATOR
Intervention: Mastery Learning (ML)
Number of subjects: 19
Study 15963119 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist treatment for 3-5 months before radical radiotherapy
Number of subjects: 32
Study 15963119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prostate cancer)
Number of subjects: 32
Study 15500759 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 46
Study 15500759 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 46
Study 11393207 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream (Temovate®) applied twice daily for 3 or 4 weeks
Number of subjects: 0
Study 9278462 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 612
Study 9278462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (tinzaparin)
Number of subjects: 612
Study 9278462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 612
Study 8495602 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoDERM (occlusive adhesive dressing)
Number of subjects: 88
Study 8495602 — intervention group
Group type: COMPARATOR
Intervention: Steristrip plus Cutiplast (conventional absorbent wound dressing)
Number of subjects: 88
Study 3501728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-8081 (10 mg)
Number of subjects: 20
Study 3501728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-8081 (25 mg)
Number of subjects: 20
Study 3501728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-8081 (50 mg)
Number of subjects: 20
Study 3501728 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (60 mg)
Number of subjects: 20
Study 3501728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29753374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400mg b.i.d. plus losartan 50mg daily
Number of subjects: 59
Study 29753374 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50mg b.i.d.
Number of subjects: 59
Study 27124410 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided neoadjuvant chemotherapy (guided‐NACT)
Number of subjects: 0
Study 27124410 — intervention group
Group type: COMPARATOR
Intervention: Conventional neoadjuvant chemotherapy (conventional‐NACT)
Number of subjects: 0
Study 26404395 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride 50 mg tablets, 3 times daily
Number of subjects: 42
Study 26404395 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride 50 mg injection (IM), twice daily
Number of subjects: 42
Study 26404395 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (PO)
Number of subjects: 42
Study 26404395 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (IM)
Number of subjects: 42
Study 26404395 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (PO and IM)
Number of subjects: 42
Study 24350692 — intervention group
Group type: EXPERIMENTAL
Intervention: DSL v4.1
Number of subjects: 200
Study 24350692 — intervention group
Group type: COMPARATOR
Intervention: NAL-NL1
Number of subjects: 200
Study 24350692 — intervention group
Group type: EXPERIMENTAL
Intervention: DSL m[i/o]
Number of subjects: 200
Study 24350692 — intervention group
Group type: COMPARATOR
Intervention: NAL-NL2
Number of subjects: 200
Study 21360537 — intervention group
Group type: EXPERIMENTAL
Intervention: Subareolar injection of methylene blue (MB)
Number of subjects: 126
Study 21360537 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritumoral injection of methylene blue (MB)
Number of subjects: 126
Study 18317199 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 60 mg
Number of subjects: 0
Study 18317199 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg
Number of subjects: 0
Study 18317199 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 17184507 — intervention group
Group type: EXPERIMENTAL
Intervention: [(13)C]‐acetate breath test (ABT) with 100 mg [(13)C]‐acetate and 200 kcal liquid meal
Number of subjects: 8
Study 17184507 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity meal (gel-forming agent added)
Number of subjects: 8
Study 17184507 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphy
Number of subjects: 8
Study 14519265 — intervention group
Group type: EXPERIMENTAL
Intervention: A.H.C.P.R. Practice Guidelines
Number of subjects: 31
Study 14519265 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 31
Study 14519265 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based recommendations
Number of subjects: 31
Study 10851707 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized inpatient stroke unit care
Number of subjects: 3864
Study 8736513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenators
Number of subjects: 20
Study 8736513 — intervention group
Group type: COMPARATOR
Intervention: Membrane oxygenators
Number of subjects: 20
Study 8736513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oxygenator types
Number of subjects: 20
Study 1484192 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine (CRM) suspension (SAR 213)
Number of subjects: 52
Study 1484192 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine (CRM) tablets (Moscontin)
Number of subjects: 52
Study 3975798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cephapirin sodium
Number of subjects: 85
Study 3975798 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics
Number of subjects: 85
Study 30656609 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation group (writing about deepest feelings, stress coping, and finding benefits)
Number of subjects: 96
Study 30656609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-fact group (writing about cancer experience objectively)
Number of subjects: 96
Study 30656609 — intervention group
Group type: COMPARATOR
Intervention: Emotional disclosure group (writing about deepest feelings)
Number of subjects: 96
Study 27885425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) - single injection 4 µg/kg before skin incision (n = 23)
Number of subjects: 49
Study 27885425 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioids (IVO) - iv remifentanil infusion during surgery followed by i.v. bolus of morphine, 0.15 mg/kg before the end of surgery (n = 26)
Number of subjects: 49
Study 26680399 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma® nail
Number of subjects: 81
Study 26680399 — intervention group
Group type: COMPARATOR
Intervention: ENDOVIS® nail
Number of subjects: 81
Study 23422395 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 59
Study 21299684 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with 0.7 ml·kg(‐1) of 1.0% lidocaine containing epinephrine at 5 μg·ml(‐1)
Number of subjects: 52
Study 21299684 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (control group)
Number of subjects: 52
Study 19193493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of structure provided by parents in middle childhood
Number of subjects: 53
Study 16401430 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity exercise program (1h/session, 3 sessions/week for 19 weeks)
Number of subjects: 63
Study 15133920 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief tailored counselling intervention
Number of subjects: 287
Study 15133920 — intervention group
Group type: COMPARATOR
Intervention: Health counselling not tailored to exercise behaviour
Number of subjects: 287
Study 11758229 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 46
Study 11758229 — intervention group
Group type: COMPARATOR
Intervention: M group and L group (moderate and major renal dysfunction)
Number of subjects: 46
Study 9218948 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg orally every 8 h for 10 days
Number of subjects: 35
Study 9218948 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 35
Study 9218948 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 35
Study 8251278 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 units of alcohol
Number of subjects: 10
Study 8251278 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 units of alcohol
Number of subjects: 10
Study 8251278 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (control)
Number of subjects: 10
Study 3307487 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 0
Study 3307487 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 ml of Alcohol per kg body weight
Number of subjects: 0
Study 3307487 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of Alcohol per kg body weight
Number of subjects: 0
Study 31756120 — intervention group
Group type: EXPERIMENTAL
Intervention: Koch compressions
Number of subjects: 18
Study 31756120 — intervention group
Group type: COMPARATOR
Intervention: Conventional compressions
Number of subjects: 18
Study 30855234 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfast broadband implementation
Number of subjects: 1388
Study 30855234 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-level discussions with general practitioners
Number of subjects: 1388
Study 30855234 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-level tailored booklets
Number of subjects: 1388
Study 30855234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1388
Study 28858134 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 200
Study 28858134 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 200
Study 26481885 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap (MWF) surgery with diode laser (DL) (810 nm)
Number of subjects: 25
Study 26481885 — intervention group
Group type: COMPARATOR
Intervention: Modified Widman flap (MWF) surgery alone
Number of subjects: 25
Study 23150720 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug chemolipiodolization with sponge embolization (Arm 1)
Number of subjects: 365
Study 23150720 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug chemolipiodolization without embolization (Arm 2)
Number of subjects: 365
Study 23150720 — intervention group
Group type: COMPARATOR
Intervention: Single-drug chemolipiodolization with sponge embolization (Arm 3)
Number of subjects: 365
Study 21631360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertilized egg powder (Young Tissue Extract; YT®)
Number of subjects: 55
Study 21631360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertilized egg powder (Young Tissue Extract; YT®) plus Melissa officinalis
Number of subjects: 55
Study 21631360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19085032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-profile port system
Number of subjects: 80
Study 19085032 — intervention group
Group type: COMPARATOR
Intervention: Regular port system (Control)
Number of subjects: 80
Study 19085032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 16699438 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses (Bausch & Lomb SofLens Multifocal)
Number of subjects: 38
Study 16699438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision contact lenses (SofLens 59)
Number of subjects: 38
Study 16699438 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 38
Study 16699438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision contact lenses
Number of subjects: 38
Study 14740177 — intervention group
Group type: COMPARATOR
Intervention: Normal MPI (SSS=0, n=153)
Number of subjects: 318
Study 14740177 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible defects (SDS≥3, n=65)
Number of subjects: 318
Study 14740177 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible defects (SDS<3 and SRS>1, n=100)
Number of subjects: 318
Study 14740177 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible defects with symptoms
Number of subjects: 318
Study 14740177 — intervention group
Group type: COMPARATOR
Intervention: Normal MPI (SSS=0)
Number of subjects: 318
Study 14740177 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible defects (SDS≥3)
Number of subjects: 318
Study 14740177 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible defects (SDS<3 and SRS>1)
Number of subjects: 318
Study 12447951 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (Group A, n = 39)
Number of subjects: 79
Study 12447951 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (Group B, n = 40)
Number of subjects: 79
Study 12447951 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients 20 years of age or less
Number of subjects: 79
Study 12447951 — intervention group
Group type: COMPARATOR
Intervention: Patients older than 20 years
Number of subjects: 79
Study 9722818 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle exchange program (NEP)
Number of subjects: 325
Study 9722818 — intervention group
Group type: COMPARATOR
Intervention: Standard referrals
Number of subjects: 325
Study 8564938 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention including health education, stress management, and coping skills teaching
Number of subjects: 61
Study 8564938 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention
Number of subjects: 61
Study 8564938 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study 2507875 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF group (n = 6) - repetitive GRF 1 micrograms/kg, IV, three times a week
Number of subjects: 8
Study 2507875 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 6) - saline injections
Number of subjects: 8
Study 16806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg
Number of subjects: 0
Study 16806 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Maalox, 30 ml, 1 and 3 hr after a meal
Number of subjects: 0
Study 31616932 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado diet (1 Hass avocado, ∼136 g per day)
Number of subjects: 45
Study 31616932 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat diet (high oleic acid oils)
Number of subjects: 45
Study 31616932 — intervention group
Group type: COMPARATOR
Intervention: Lower-fat diet
Number of subjects: 45
Study 30670518 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation for CRRT
Number of subjects: 1450
Study 30670518 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation for CRRT
Number of subjects: 1450
Study 27314311 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-focused mortality salience
Number of subjects: 0
Study 27314311 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-focused mortality salience
Number of subjects: 0
Study 27314311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 25611313 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat plus paclitaxel/carboplatin (group A)
Number of subjects: 89
Study 25611313 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin alone (group B)
Number of subjects: 89
Study 24488582 — intervention group
Group type: EXPERIMENTAL
Intervention: lynestrenol (LYN) 15 mg/d
Number of subjects: 60
Study 24488582 — intervention group
Group type: COMPARATOR
Intervention: micronized progesterone (MP) 200 mg/d
Number of subjects: 60
Study 24488582 — intervention group
Group type: EXPERIMENTAL
Intervention: lynestrenol (LYN)
Number of subjects: 60
Study 24488582 — intervention group
Group type: COMPARATOR
Intervention: micronized progesterone (MP)
Number of subjects: 60
Study 24488582 — intervention group
Group type: EXPERIMENTAL
Intervention: lynestrenol (LYN) and micronized progesterone (MP)
Number of subjects: 60
Study 23082173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent IL-2
Number of subjects: 267
Study 23082173 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 267
Study 20804358 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation (full-time occlusion discontinued completely at the start of the study)
Number of subjects: 20
Study 20804358 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy tapering (occlusion reduced from full-time to 50% of waking hours, then to 25%, and discontinued at week 8)
Number of subjects: 20
Study 20804358 — intervention group
Group type: COMPARATOR
Intervention: Both groups (abrupt cessation and therapy tapering)
Number of subjects: 20
Study 18091051 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + efaproxiral
Number of subjects: 106
Study 18091051 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 106
Study 15304276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride cement
Number of subjects: 90
Study 15304276 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous coated press‐fit cup with ceramic coating
Number of subjects: 90
Study 15304276 — intervention group
Group type: COMPARATOR
Intervention: Palacos cum Gentamicin cement
Number of subjects: 90
Study 15304276 — intervention group
Group type: COMPARATOR
Intervention: Cemented cups
Number of subjects: 90
Study 15304276 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented cups
Number of subjects: 90
Study 11488185 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for breast cancer with mammography (WE study)
Number of subjects: 0
Study 11488185 — intervention group
Group type: COMPARATOR
Intervention: Alternative statistical analysis of WE study
Number of subjects: 0
Study 9612666 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 0
Study 7853130 — intervention group
Group type: EXPERIMENTAL
Intervention: M + SRP
Number of subjects: 51
Study 7853130 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 51
Study 7853130 — intervention group
Group type: EXPERIMENTAL
Intervention: M
Number of subjects: 51
Study 7853130 — intervention group
Group type: COMPARATOR
Intervention: NoTx
Number of subjects: 51
Study 29532635 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts incorporated in gels (protein, fiber, lipid)
Number of subjects: 5
Study 29532635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gels rich in precursors (glucoraphanin and glucoiberin)
Number of subjects: 5
Study 29532635 — intervention group
Group type: COMPARATOR
Intervention: Control broccoli sprout
Number of subjects: 5
Study 27689900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management (CBSM)
Number of subjects: 51
Study 27689900 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation control group
Number of subjects: 51
Study 24901128 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) and laparoscopic common bile duct exploration (LCBDE) plus T‐tube drainage (group LT)
Number of subjects: 178
Study 24901128 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) and laparoscopic common bile duct exploration (LCBDE) with endonasobiliary drainage (ENBD) tube (group LE)
Number of subjects: 178
Study 24901128 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy with ENBD followed by LC (group EE)
Number of subjects: 178
Study 24901128 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐tube drainage of open CBDE (group OT)
Number of subjects: 178
Study 21940695 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections to parotid and submandibular glands (5 individuals)
Number of subjects: 6
Study 21940695 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections to submandibular glands only (1 individual)
Number of subjects: 6
Study 21940695 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects reported
Number of subjects: 6
Study 20227758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg subcutaneously every week for 26 weeks
Number of subjects: 51
Study 20227758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 20227758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 51
Study 18349870 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cannabis
Number of subjects: 0
Study 18349870 — intervention group
Group type: EXPERIMENTAL
Intervention: Further trials of cannabis
Number of subjects: 0
Study 17015055 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioguanine
Number of subjects: 1492
Study 17015055 — intervention group
Group type: COMPARATOR
Intervention: Mercaptopurine
Number of subjects: 1492
Study 14523294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week-on, 1-week-off therapy
Number of subjects: 600
Study 14523294 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple nucleotide therapy
Number of subjects: 600
Study 14523294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 600
Study 14523294 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 600
Study 14523294 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine, Stavudine, Saquinavir, Ritonavir
Number of subjects: 600
Study 10797160 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention group (n=58)
Number of subjects: 114
Study 10797160 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n=56)
Number of subjects: 114